Alteration of Gut Microbiota and Its Impact on Immune Response in Patients with Chronic HBV Infection: A Review

References

• Wang J, Wang Y, Zhang X, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Front Microbiol. 2017;8:2222. doi:10.3389/fmicb.2017.0222229180991
   PubMed Web of Science ®Google Scholar
• Rajoriya N, Combet C, Zoulim F, Janssen HL. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualized approach? J Hepatol. 2017;67(6):1281–1297. doi:10.1016/j.jhep.2017.07.01128736138
   PubMed Web of Science ®Google Scholar
• Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013;10(1):239. doi:10.1186/1743-422X-10-23923870415
   PubMed Web of Science ®Google Scholar
• Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 2014;57(3–4):141–150. doi:10.1159/00036094725034481
   PubMed Web of Science ®Google Scholar
• Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64(1).
   Web of Science ®Google Scholar
• Peters MG. Hepatitis B virus infection: what is current and new. Top Antivir Med. 2019;26(4):112.30641484
   PubMedGoogle Scholar
• Bonino F, Piratvisuth T, Brunetto MR, Liaw Y-F. Diagnostic markers of chronic hepatitis B infection and disease. Antivir Ther. 2010;15(3):35. doi:10.3851/IMP162221041902
   PubMed Web of Science ®Google Scholar
• Pardee M. Diagnosis and management of hepatitis B and C. Nurs Clin. 2019;54(2):277–284. doi:10.1016/j.cnur.2019.02.004
   Web of Science ®Google Scholar
• Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci. 2019;20(2):395. doi:10.3390/ijms20020395
   PubMed Web of Science ®Google Scholar
• Yuen M-F, Ahn SH, Chen D-S, et al. Chronic hepatitis B virus infection. J Clin Gastroenterol. 2016;50(4):286–294. doi:10.1097/MCG.000000000000047826840752
   PubMed Web of Science ®Google Scholar
• Yang R, Xu Y, Dai Z, Lin X, Wang H. The immunologic role of gut microbiota in patients with chronic HBV infection. J Immunol Res. 2018;2018:1–6. doi:10.1155/2018/2361963
   Web of Science ®Google Scholar
• Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513–1524. doi:10.1053/j.gastro.2014.01.02024440671
   PubMed Web of Science ®Google Scholar
• Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, Triantos CK, Thomopoulos KC. Intestinal barrier dysfunction in cirrhosis: current concepts in pathophysiology and clinical implications. World J Hepatol. 2015;7(17):2058–2068. doi:10.4254/wjh.v7.i17.205826301048
   PubMed Web of Science ®Google Scholar
• Kang Y, Cai Y. Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for fecal microbiota transplantation therapy. J Hospital Infect. 2017;96(4):342–348. doi:10.1016/j.jhin.2017.04.007
   Web of Science ®Google Scholar
• Organization WH. Global hepatitis report 2017: World Health Organization; 2017.
   Google Scholar
• Kumar A, Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virol J. 2014;11(1):22. doi:10.1186/1743-422X-11-2224507433
   PubMed Web of Science ®Google Scholar
• Xu D, Huang Y, Wang J. Gut microbiota modulate the immune effect against hepatitis B virus infection. Eur J Clin Microbiol Infect Dis. 2015;34(11):2139–2147. doi:10.1007/s10096-015-2464-026272175
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5(461):1–8. doi:10.3389/fimmu.2014.0046124474949
   PubMed Web of Science ®Google Scholar
• Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol. 2015;204(1):11–20. doi:10.1007/s00430-014-0370-125550115
   PubMed Web of Science ®Google Scholar
• Ma Z, Zhang E, Yang D, Lu M. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol. 2015;12(3):273. doi:10.1038/cmi.2014.11225418467
   PubMed Web of Science ®Google Scholar
• Tsai K-N, Kuo C-F, Ou J-HJ. Mechanisms of hepatitis B virus persistence. Trends Microbiol. 2018;26(1):33–42. doi:10.1016/j.tim.2017.07.00628823759
   PubMed Web of Science ®Google Scholar
• Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859–904. doi:10.1152/physrev.00045.200920664075
   PubMed Web of Science ®Google Scholar
• Mazagova M, Wang L, Anfora AT, et al. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 2014;29(3):1043–1055. doi:10.1096/fj.14-25951525466902
   PubMed Web of Science ®Google Scholar
• Zhu Q, Xia P, Zhou X, et al. Hepatitis B virus infection alters gut microbiota composition in mice. Front Cell Infect Microbiol. 2019;9:377. doi:10.3389/fcimb.2019.0037731750262
   PubMed Web of Science ®Google Scholar
• Chou -H-H, Chien W-H, Wu -L-L, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Nat Acad Sci. 2015;112(7):2175–2180. doi:10.1073/pnas.142477511225646429
   PubMed Web of Science ®Google Scholar
• Korpela K, Salonen A, Virta LJ, et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat Commun. 2016;7:10410. doi:10.1038/ncomms1041026811868
   PubMed Web of Science ®Google Scholar
• Ren YD, Ye ZS, Yang LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e‐antigen (HBeAg) clearance in patients with positive HBeAg after long‐term antiviral therapy. Hepatology. 2017;65(5):1765–1768. doi:10.1002/hep.2900828027582
   PubMed Web of Science ®Google Scholar
• Bajaj JS. The role of microbiota in hepatic encephalopathy. Gut Microbes. 2014;5(3):397–403. doi:10.4161/gmic.2868424690956
   PubMed Web of Science ®Google Scholar
• Chassaing B, Etienne‐Mesmin L, Gewirtz AT. Microbiota‐liver axis in hepatic disease. Hepatology. 2014;59(1):328–339. doi:10.1002/hep.2649423703735
   PubMed Web of Science ®Google Scholar
• Minemura M, Shimizu Y. Gut microbiota and liver diseases. WJG. 2015;21(6):1691. doi:10.3748/wjg.v21.i6.169125684933
   PubMed Web of Science ®Google Scholar
• Bhat M, Arendt BM, Bhat V, Renner EL, Humar A, Allard JP. Implication of the intestinal microbiome in complications of cirrhosis. World J Hepatol. 2016;8(27):1128. doi:10.4254/wjh.v8.i27.112827721918
   PubMedGoogle Scholar
• Liu Q, Li F, Zhuang Y, et al. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathog. 2019;11(1):1. doi:10.1186/s13099-018-0281-630675188
   PubMed Web of Science ®Google Scholar
• Wang Y, Pan CQ, Xing H. Advances in gut microbiota of viral hepatitis cirrhosis. Biomed Res Int. 2019;2019.
   Web of Science ®Google Scholar
• Fukui H. Gut microbiota and host reaction in liver diseases. Microorganisms. 2015;3(4):759–791. doi:10.3390/microorganisms304075927682116
   PubMedGoogle Scholar
• Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019;69(1):107–120. doi:10.1002/hep.3003629665135
   PubMed Web of Science ®Google Scholar
• Lin R, Zhou L, Zhang J, Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol. 2015;8(5):5153.26191211
   PubMed Web of Science ®Google Scholar
• Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013;29(3):264. doi:10.1097/MOG.0b013e32835ff94823493073
   PubMed Web of Science ®Google Scholar
• Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012;56(6):1283–1292. doi:10.1016/j.jhep.2012.01.01922326468
   PubMed Web of Science ®Google Scholar
• Wei X, Yan X, Zou D, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol. 2013;13(1):175. doi:10.1186/1471-230X-13-17524369878
   PubMed Web of Science ®Google Scholar
• Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Microb Ecol. 2011;61(3):693–703. doi:10.1007/s00248-010-9801-821286703
   PubMed Web of Science ®Google Scholar
• Yun Y, Chang Y, Kim H-N, et al. Alterations of the gut microbiome in chronic hepatitis B virus infection associated with alanine aminotransferase level. J Clin Med. 2019;8(2):173. doi:10.3390/jcm8020173
   Web of Science ®Google Scholar
• Chen Y, Qin N, Guo J, et al. Functional gene array-based analysis of fecal microbiomes in patients with liver cirrhosis. BMC Genom. 2014;15(1):753. doi:10.1186/1471-2164-15-753
   Web of Science ®Google Scholar
• Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562–572. doi:10.1002/hep.2442321574172
   PubMed Web of Science ®Google Scholar
• Chen J, Wei Y, He J, et al. Natural killer T cells play a necessary role in modulating immune-mediated liver injury by gut microbiota. Sci Rep. 2014;4:7259. doi:10.1038/srep0725925435303
   PubMed Web of Science ®Google Scholar
• Cinar MU, Islam MA, Pröll M, et al. Evaluation of suitable reference genes for gene expression studies in porcine PBMCs in response to LPS and LTA. BMC Res Notes. 2013;6(1):56. doi:10.1186/1756-0500-6-5623394600
   PubMedGoogle Scholar
• Bermudez-Brito M, Muñoz-Quezada S, Gomez-Llorente C, et al. Cell-free culture supernatant of Bifidobacterium breve CNCM I-4035 decreases pro-inflammatory cytokines in human dendritic cells challenged with Salmonella typhi through TLR activation. PLoS One. 2013;8(3):e59370. doi:10.1371/journal.pone.005937023555025
   PubMed Web of Science ®Google Scholar
• Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012;590(3):447–458. doi:10.1113/jphysiol.2011.21969122124143
   PubMed Web of Science ®Google Scholar
• Frazier TH, DiBaise JK, McClain CJ. Gut microbiota, intestinal permeability, obesity‐induced inflammation, and liver injury. J Parenteral Enteral Nutr. 2011;35:14S–20S. doi:10.1177/0148607111413772
   PubMedGoogle Scholar
• Allam NG, Salem ML, Elbatae H, Nabieh MM. Lactobacillus acidophilus and Bifidobacteria spp having antibacterial and antiviral effects on chronic HCV infection. African Journal of Microbiology Research. 2019;13(5):77–90.
   Google Scholar
• Luedde T, Schwabe RF. NF-κB in the liver—linking injury, fibrosis, and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(2):108. doi:10.1038/nrgastro.2010.21321293511
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373. doi:10.1038/ni.186320404851
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1754. doi:10.1177/1758835919848184
   Web of Science ®Google Scholar
• Taur Y, Coyte K, Schluter J, et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med. 2018;10(460):9489. doi:10.1126/scitranslmed.aap9489
   Web of Science ®Google Scholar
• Cesaro C, Tiso A, Del Prete A, et al. Gut microbiota and probiotics in chronic liver diseases. Digestive Liver Dis. 2011;43(6):431–438. doi:10.1016/j.dld.2010.10.015
   Web of Science ®Google Scholar
• Kirpich IA, McClain CJ. Probiotics in the treatment of liver diseases. J Am Coll Nutr. 2012;31(1):14–23. doi:10.1080/07315724.2012.1072000422661622
   PubMed Web of Science ®Google Scholar
• Nitin J, Mithun S, Rao P, Nageshwar Reddy D. Liver diseases: the role of gut microbiota and probiotics. J Prob Health. 2016;4(154):2. doi:10.4172/2329-8901.1000154
   Google Scholar
• Elzouki A-N. Probiotics and liver disease: where are we now and where are we going? J Clin Gastroenterol. 2016;50:188–190. doi:10.1097/MCG.0000000000000712
   Web of Science ®Google Scholar
• Sharma V, Garg S, Aggarwal S. Probiotics and liver disease. Perm J. 2013;17(4):62. doi:10.7812/TPP/12-14424361022
   PubMedGoogle Scholar
• Butel M-J. Probiotics, gut microbiota and health. Médecine et maladies infectieuses. 2014;44(1):1–8. doi:10.1016/j.medmal.2013.10.002
   PubMed Web of Science ®Google Scholar
• Ganguly N, Bhattacharya S, Sesikeran B, et al. ICMR-DBT guidelines for evaluation of probiotics in food. Indian J Med Res. 2011;134(1):22.21808130
   PubMed Web of Science ®Google Scholar
• Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491. doi:10.1038/nrgastro.2017.7528611480
   PubMed Web of Science ®Google Scholar
• Chen C, Li L, Wu Z, Chen H, Fu S. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis. J Infect. 2007;54(1):98–102. doi:10.1016/j.jinf.2005.11.01317049992
   PubMed Web of Science ®Google Scholar